PL2939661T3 - Nowy preparat mikrogranulkowy - Google Patents

Nowy preparat mikrogranulkowy

Info

Publication number
PL2939661T3
PL2939661T3 PL13869051.6T PL13869051T PL2939661T3 PL 2939661 T3 PL2939661 T3 PL 2939661T3 PL 13869051 T PL13869051 T PL 13869051T PL 2939661 T3 PL2939661 T3 PL 2939661T3
Authority
PL
Poland
Prior art keywords
novel
microgranular formulation
microgranular
formulation
novel microgranular
Prior art date
Application number
PL13869051.6T
Other languages
English (en)
Inventor
Young Sam Goo
Jeong Tae Kim
Original Assignee
Corepharm Co., Ltd.
Corepharmbio Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corepharm Co., Ltd., Corepharmbio Co., Ltd. filed Critical Corepharm Co., Ltd.
Publication of PL2939661T3 publication Critical patent/PL2939661T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
PL13869051.6T 2012-12-31 2013-12-27 Nowy preparat mikrogranulkowy PL2939661T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120158709A KR101340733B1 (ko) 2012-12-31 2012-12-31 신규한 마이크로그래뉼 제형
PCT/KR2013/012346 WO2014104840A1 (ko) 2012-12-31 2013-12-27 신규한 마이크로그래뉼 제형

Publications (1)

Publication Number Publication Date
PL2939661T3 true PL2939661T3 (pl) 2023-03-20

Family

ID=49988132

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13869051.6T PL2939661T3 (pl) 2012-12-31 2013-12-27 Nowy preparat mikrogranulkowy

Country Status (8)

Country Link
US (1) US20150328167A1 (pl)
EP (1) EP2939661B1 (pl)
JP (1) JP6537185B2 (pl)
KR (1) KR101340733B1 (pl)
CN (1) CN104936580A (pl)
ES (1) ES2939889T3 (pl)
PL (1) PL2939661T3 (pl)
WO (1) WO2014104840A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112336690B (zh) * 2020-12-10 2022-10-11 浙江海翔药业股份有限公司 一种盐酸克林霉素棕榈酸酯颗粒及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
US20010056177A1 (en) * 1997-12-20 2001-12-27 Becker Nathaniel T. Matrix granule
CN1116877C (zh) * 1999-10-28 2003-08-06 东北制药厂 可经口腔粘膜吸收的卡前列甲酯制剂及其制备方法
WO2003074029A1 (en) * 2002-03-07 2003-09-12 Vectura Limited Fast melt multiparticulate formulations for oral delivery
AU2003249478A1 (en) * 2002-07-19 2004-02-09 Ranbaxy Laboratories Limited Taste masked sumatriptan tablets and processes for their preparation
AR040157A1 (es) * 2003-06-06 2005-03-16 Rodriguez Julio Cesar Una formulacion en microgranulos para administracion oral en suspension acuosa
KR20120136430A (ko) * 2004-04-08 2012-12-18 교와 핫꼬 기린 가부시키가이샤 안정성이 향상된 고형 제제 및 그 제조 방법
US7858609B2 (en) * 2005-11-28 2010-12-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
JP5276991B2 (ja) * 2006-04-27 2013-08-28 武田薬品工業株式会社 固形製剤
NZ574544A (en) * 2006-08-04 2011-12-22 Ethypharm Sa Granule and orally disintegrating tablet comprising oxycodone
KR101109633B1 (ko) * 2007-08-03 2012-01-31 제이더블유중외제약 주식회사 활성성분의 코팅막이 보호되는 구강내붕해제형을 제조하기위한 조성물
BRPI0820997A2 (pt) * 2007-12-10 2014-12-23 Eurand Inc Comprimidos de desintegração oral compreendendo difenidramina.
WO2010053306A2 (ko) * 2008-11-07 2010-05-14 주식회사 삼양사 메칠페니데이트의 방출 제어용 약제학적 조성물
MX339136B (es) * 2008-12-12 2016-05-13 Rhein Siegfried Sa De Cv Composicion de liberacion pulsatil de sildenafil y proceso para prepararla.
EP2515882A2 (en) * 2009-12-22 2012-10-31 Abbot Healthcare Private Limited Controlled release pharmaceutical composition
JP5694315B2 (ja) * 2010-06-15 2015-04-01 株式会社ナリス化粧品 ゼデロン又はゼデロン類縁物質を有効成分として含む美白用の食品及び経口投与剤
JP4803686B2 (ja) 2010-08-31 2011-10-26 協和発酵キリン株式会社 苦味を呈する薬物を含有する顆粒および口腔内崩壊錠
CN107028900A (zh) 2010-12-02 2017-08-11 艾戴尔医药公司 快速分散颗粒、口腔崩解片以及方法

Also Published As

Publication number Publication date
WO2014104840A1 (ko) 2014-07-03
EP2939661B1 (en) 2022-11-23
US20150328167A1 (en) 2015-11-19
JP2016504354A (ja) 2016-02-12
EP2939661A4 (en) 2016-08-03
KR101340733B1 (ko) 2013-12-12
EP2939661A1 (en) 2015-11-04
ES2939889T3 (es) 2023-04-27
JP6537185B2 (ja) 2019-07-03
CN104936580A (zh) 2015-09-23

Similar Documents

Publication Publication Date Title
IL235966A0 (en) Antibody formulation
IL233530A0 (en) cosmetic
GB201215289D0 (en) Nanoparticle formulation
GB201216800D0 (en) Novel use
ZA201306000B (en) Stable formulation
IL237636A0 (en) new uses
ZA201409020B (en) Pharmaceutical formulation
SG11201504134SA (en) External preparation
EP2821058A4 (en) COSMETIC
GB201320432D0 (en) Novel formulation
EP2821059A4 (en) COSMETIC
EP2928903A4 (en) OLIGONUKLEOTIDREZEPTUR
PL2898027T3 (pl) Formulacje farb
PL2662093T3 (pl) Preparat tobramycyny
EP2839835A4 (en) ENCAPSULATED FORMULATION
GB201317718D0 (en) Novel formulation
ZA201408114B (en) Oral formulation
IL236574A0 (en) formulation of misoprostol
PL2908859T3 (pl) Formulacje arypiprazolu
PL2939661T3 (pl) Nowy preparat mikrogranulkowy
GB201212463D0 (en) Novel use
GB201211247D0 (en) Improved formulation
GB201206178D0 (en) Formulations
GB201211790D0 (en) Adjuvanted formulation
GB201202256D0 (en) Novel use